AN2 Therapeutics, Inc. (ANTX)
5.69
-0.29
(-4.85%)
USD |
NASDAQ |
Sep 09, 13:39
AN2 Therapeutics Enterprise Value : 138.74M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 138.74M |
| September 04, 2026 | 135.47M |
| September 03, 2026 | 137.65M |
| September 02, 2026 | 137.65M |
| September 01, 2026 | 120.58M |
| August 31, 2026 | 123.13M |
| August 28, 2026 | 124.22M |
| August 27, 2026 | 130.02M |
| August 26, 2026 | 122.40M |
| August 25, 2026 | 127.12M |
| August 24, 2026 | 126.03M |
| August 21, 2026 | 132.57M |
| August 20, 2026 | 131.84M |
| August 19, 2026 | 138.01M |
| August 18, 2026 | 138.38M |
| August 17, 2026 | 129.66M |
| August 14, 2026 | 139.10M |
| August 13, 2026 | 138.74M |
| August 12, 2026 | 149.63M |
| August 11, 2026 | 134.75M |
| August 10, 2026 | 136.20M |
| August 07, 2026 | 136.92M |
| August 06, 2026 | 142.37M |
| August 05, 2026 | 133.66M |
| August 04, 2026 | 137.29M |
| Date | Value |
|---|---|
| August 03, 2026 | 124.22M |
| July 31, 2026 | 115.86M |
| July 30, 2026 | 115.14M |
| July 29, 2026 | 103.88M |
| July 28, 2026 | 92.26M |
| July 27, 2026 | 100.61M |
| July 24, 2026 | 100.25M |
| July 23, 2026 | 100.25M |
| July 22, 2026 | 99.16M |
| July 21, 2026 | 103.16M |
| July 20, 2026 | 95.89M |
| July 17, 2026 | 91.54M |
| July 16, 2026 | 91.17M |
| July 15, 2026 | 91.17M |
| July 14, 2026 | 94.44M |
| July 13, 2026 | 86.82M |
| July 10, 2026 | 85.00M |
| July 09, 2026 | 89.72M |
| July 08, 2026 | 81.73M |
| July 07, 2026 | 77.74M |
| July 06, 2026 | 81.73M |
| July 02, 2026 | 82.10M |
| July 01, 2026 | 92.26M |
| June 30, 2026 | 97.35M |
| June 29, 2026 | 95.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 15.37M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 33.22M |
| Fulcrum Therapeutics, Inc. | -22.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.185M |
| Total Expenses (Quarterly) | 8.185M |
| EPS Diluted (Quarterly) | -0.1829 |
| Earnings Yield | -18.86% |
| Normalized Earnings Yield | -18.86 |